BioLogic Equity Research

BioLogic Equity Research is a research and consulting firm focused on fundamental analysis of the healthcare sector including biotechnology, pharmaceuticals and medical technology. We concentrate on early and mid-stage biotechnology and medical technology companies. BER's stock selection criteria is skewed toward high-alpha binary events such as FDA regulatory action dates, clinical data releases and potentially disruptive products either entering markets or in late-stage development.